FIGO 2023分期标准对早期子宫内膜癌分期迁移和生存结局的影响:一项回顾性队列研究
该回顾性队列研究将538例2015年5月至2023年7月接受手术分期的子宫内膜癌患者从FIGO 2009重新分期为FIGO 2023,评估分期迁移和预后能力。26.8%的病例发生分期迁移(n=144),几乎均为上调(n=143,99.3%)。FIGO 2023 II期各亚期之间OS和PFS无显著差异,但IIC和IICmp53abn按初始FIGO 2009亚期分层后生存差异显著。
要点
- FIGO 2023分期导致26.8%病例分期迁移,几乎均为上调(99.3%)。
- FIGO 2023 II期各亚期之间OS和PFS无显著差异。
- IIC和IICmp53abn按FIGO 2009亚期分层后生存差异显著,提示异质性。
核心结论
- FIGO 2023分期修订因纳入淋巴血管间隙浸润、组织学和分子特征,导致从IA/IB到II期的显著上调。
- FIGO 2023 II期各亚期之间未发现生存显著差异,提示缺乏区分能力。
- IIC和IICmp53abn按初始FIGO 2009亚期分层后生存差异显著,提示FIGO 2023 IIC和IICmp53abn为异质性队列。
研究设计与样本
- 回顾性队列研究,纳入2015年5月至2023年7月接受子宫内膜癌手术分期(包括前哨淋巴结活检或淋巴结清扫术)的患者,从FIGO 2009重新分期为FIGO 2023(n=538)。
主要发现
- 26.8%的病例发生分期迁移(n=144),几乎均为上调(n=143,99.3%)。
- 上调包括从IA期迁移至II期(97/301,32.2%)和从IB期迁移至II期(46/85,54.1%)。
- FIGO 2023 II期各亚期(IIA vs. IIB vs. IIC vs. IICmp53abn)之间OS和PFS无显著差异(pOS=0.53,pPFS=0.59)。
- FIGO 2023 IIC和IICmp53abn按初始FIGO 2009亚期分层(52例IIC:23例IA、21例IB、8例II;101例IICmp53abn:67例IA、17例IB、17例II),FIGO 2009亚期IA vs. IB vs. II之间OS和PFS差异显著(p<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the revised FIGO 2023 endometrial cancer (EC) staging system to the previous FIGO 2009 schema, assessing stage migration and prognostic capability. METHODS: Patients who underwent EC surgical staging (including sentinel lymph node biopsy or lymphadenectomy) between May 2015 and July 2023 were restaged from FIGO 2009 to FIGO 2023 (n = 538). Overall survival (OS) and progression-free survival (PFS) for substages were estimated using the Kaplan-Meier method and compared using log-rank test. RESULTS: Stage migration occureed in 26.8 % of cases (n = 144) with almost all upstaged (n = 143, 99.3 %). Upstaging included migration from stage IA to II (97/301, 32.2 %) and stage IB to II (46/85, 54.1 %). No significant differences in OS or PFS were noted between FIGO 2023 stage II substages (IIA vs. IIB vs. IIC vs. IICmp53abn; pOS = 0.53 and pPFS = 0.59). When FIGO 2023 stage IIC and IICmp53abn were stratified by initial FIGO 2009 substages (52 IIC: 23 IA, 21 IB, 8 II; and 101 IICmp53abn: 67 IA, 17 IB, 17 II), significant differences in OS and PFS were identified between FIGO 2009 substages IA vs. IB vs. II (p < 0.05). CONCLUSIONS: The FIGO 2023 EC staging revision has resulted in significant upstaging from IA/IB to II, due to incorporation of lymphovascular space invasion, histology, and molecular profiles. No significant differences in survival were found between FIGO 2023 stage II substages, suggesting lack of discriminatory ability. Significant survival differences were seen within stages IIC and IICmp53abn when stratified by initial FIGO 2009 substages, suggesting FIGO 2023 IIC and IICmp53abn are heterogeneous cohorts.
引用
- Lim JW, Dzyubak O, Moshkovich M, et al. Impact of FIGO 2023 staging criteria on stage migration and survival outcomes in early-stage endometrial cancer: A retrospective cohort study. Gynecol Oncol. 2025. PMID: 41056582. doi:10.1016/j.ygyno.2025.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。